FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365457063> ?p ?o ?g. }

• W4365457063 endingPage "964" @default.
• W4365457063 startingPage "956" @default.
• W4365457063 abstract "Rift Valley fever is a viral epidemic illness prevalent in Africa that can be fatal or result in debilitating sequelae in humans. No vaccines are available for human use. We aimed to evaluate the safety and immunogenicity of a non-replicating simian adenovirus-vectored Rift Valley fever (ChAdOx1 RVF) vaccine in humans.We conducted a phase 1, first-in-human, open-label, dose-escalation trial in healthy adults aged 18-50 years at the Centre for Clinical Vaccinology and Tropical Medicine, Oxford, UK. Participants were required to have no serious comorbidities or previous history of receiving an adenovirus-based vaccine before enrolment. Participants were non-randomly allocated to receive a single ChAdOx1 RVF dose of either 5 × 109 virus particles (vp), 2·5 × 1010 vp, or 5 × 1010 vp administered intramuscularly into the deltoid of their non-dominant arm; enrolment was sequential and administration was staggered to allow for safety to be assessed before progression to the next dose. Primary outcome measures were assessment of adverse events and secondary outcome measures were Rift Valley fever neutralising antibody titres, Rift Valley fever GnGc-binding antibody titres (ELISA), and cellular response (ELISpot), analysed in all participants who received a vaccine. This trial is registered with ClinicalTrials.gov (NCT04754776).Between June 11, 2021, and Jan 13, 2022, 15 volunteers received a single dose of either 5 × 109 vp (n=3), 2·5 × 1010 vp (n=6), or 5 × 1010 vp (n=6) ChAdOx1 RVF. Nine participants were female and six were male. 14 (93%) of 15 participants reported solicited local adverse reactions; injection-site pain was the most frequent (13 [87%] of 15). Ten (67%) of 15 participants (from the 2·5 × 1010 vp and 5 × 1010 vp groups only) reported systemic symptoms, which were mostly mild in intensity, the most common being headache (nine [60%] of 15) and fatigue (seven [47%]). All unsolicited adverse events reported within 28 days were either mild or moderate in severity; gastrointestinal symptoms were the most common reaction (at least possibly related to vaccination), occurring in four (27%) of 15 participants. Transient decreases in total white cell, lymphocyte, or neutrophil counts occurred at day 2 in some participants in the intermediate-dose and high-dose groups. Lymphopenia graded as severe occurred in two participants in the 5 × 1010 vp group at a single timepoint, but resolved at the subsequent follow-up visit. No serious adverse events occurred. Rift Valley fever neutralising antibodies were detectable across all dose groups, with all participants in the 5 × 1010 vp dose group having high neutralising antibody titres that peaked at day 28 after vaccination and persisted through the 3-month follow-up. High titres of binding IgG targeting Gc glycoprotein were detected whereas those targeting Gn were comparatively low. IFNγ cellular responses against Rift Valley fever Gn and Gc glycoproteins were observed in all participants except one in the 5 × 1010 vp dose group. These IFNγ responses peaked at 2 weeks after vaccination, were highest in the 5 × 1010 vp dose group, and tended to be more frequent against the Gn glycoprotein.ChAdOx1 RVF was safe, well tolerated, and immunogenic when administered as a single dose in this study population. The data support further clinical development of ChAdOx1 RVF for human use.UK Department of Health and Social Care through the UK Vaccines Network, Oak Foundation, and the Wellcome Trust.For the Swahili translation of the abstract see Supplementary Materials section." @default.
• W4365457063 created "2023-04-15" @default.
• W4365457063 creator A5002103968 @default.
• W4365457063 creator A5004794920 @default.
• W4365457063 creator A5021492528 @default.
• W4365457063 creator A5033735799 @default.
• W4365457063 creator A5037138357 @default.
• W4365457063 creator A5038203672 @default.
• W4365457063 creator A5040183990 @default.
• W4365457063 creator A5040896653 @default.
• W4365457063 creator A5047459331 @default.
• W4365457063 creator A5050591423 @default.
• W4365457063 creator A5051553404 @default.
• W4365457063 creator A5052001803 @default.
• W4365457063 creator A5056499125 @default.
• W4365457063 creator A5057807377 @default.
• W4365457063 creator A5073485372 @default.
• W4365457063 creator A5077833051 @default.
• W4365457063 creator A5078622476 @default.
• W4365457063 creator A5085474393 @default.
• W4365457063 creator A5089192522 @default.
• W4365457063 date "2023-08-01" @default.
• W4365457063 modified "2023-10-14" @default.
• W4365457063 title "Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial" @default.
• W4365457063 cites W1965835888 @default.
• W4365457063 cites W1987897968 @default.
• W4365457063 cites W2035760671 @default.
• W4365457063 cites W2038193227 @default.
• W4365457063 cites W2074279886 @default.
• W4365457063 cites W2137533253 @default.
• W4365457063 cites W2147060534 @default.
• W4365457063 cites W2210798235 @default.
• W4365457063 cites W2287101694 @default.
• W4365457063 cites W2429243658 @default.
• W4365457063 cites W2472250013 @default.
• W4365457063 cites W2525465524 @default.
• W4365457063 cites W2790688633 @default.
• W4365457063 cites W2913328568 @default.
• W4365457063 cites W2958578463 @default.
• W4365457063 cites W2980333031 @default.
• W4365457063 cites W3090844627 @default.
• W4365457063 cites W3093320156 @default.
• W4365457063 cites W3152490217 @default.
• W4365457063 cites W3166408101 @default.
• W4365457063 cites W3168944582 @default.
• W4365457063 cites W3203037871 @default.
• W4365457063 cites W3210484868 @default.
• W4365457063 cites W4206684097 @default.
• W4365457063 cites W4220854259 @default.
• W4365457063 cites W4296371042 @default.
• W4365457063 cites W4307776851 @default.
• W4365457063 cites W4308679225 @default.
• W4365457063 cites W2011571549 @default.
• W4365457063 doi "https://doi.org/10.1016/s1473-3099(23)00068-3" @default.
• W4365457063 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37060917" @default.
• W4365457063 hasPublicationYear "2023" @default.
• W4365457063 type Work @default.
• W4365457063 citedByCount "1" @default.
• W4365457063 countsByYear W43654570632023 @default.
• W4365457063 crossrefType "journal-article" @default.
• W4365457063 hasAuthorship W4365457063A5002103968 @default.
• W4365457063 hasAuthorship W4365457063A5004794920 @default.
• W4365457063 hasAuthorship W4365457063A5021492528 @default.
• W4365457063 hasAuthorship W4365457063A5033735799 @default.
• W4365457063 hasAuthorship W4365457063A5037138357 @default.
• W4365457063 hasAuthorship W4365457063A5038203672 @default.
• W4365457063 hasAuthorship W4365457063A5040183990 @default.
• W4365457063 hasAuthorship W4365457063A5040896653 @default.
• W4365457063 hasAuthorship W4365457063A5047459331 @default.
• W4365457063 hasAuthorship W4365457063A5050591423 @default.
• W4365457063 hasAuthorship W4365457063A5051553404 @default.
• W4365457063 hasAuthorship W4365457063A5052001803 @default.
• W4365457063 hasAuthorship W4365457063A5056499125 @default.
• W4365457063 hasAuthorship W4365457063A5057807377 @default.
• W4365457063 hasAuthorship W4365457063A5073485372 @default.
• W4365457063 hasAuthorship W4365457063A5077833051 @default.
• W4365457063 hasAuthorship W4365457063A5078622476 @default.
• W4365457063 hasAuthorship W4365457063A5085474393 @default.
• W4365457063 hasAuthorship W4365457063A5089192522 @default.
• W4365457063 hasBestOaLocation W43654570631 @default.
• W4365457063 hasConcept C126322002 @default.
• W4365457063 hasConcept C147483822 @default.
• W4365457063 hasConcept C159047783 @default.
• W4365457063 hasConcept C159654299 @default.
• W4365457063 hasConcept C167672396 @default.
• W4365457063 hasConcept C197934379 @default.
• W4365457063 hasConcept C203014093 @default.
• W4365457063 hasConcept C22070199 @default.
• W4365457063 hasConcept C2522874641 @default.
• W4365457063 hasConcept C2778960357 @default.
• W4365457063 hasConcept C2779053233 @default.
• W4365457063 hasConcept C2780868878 @default.
• W4365457063 hasConcept C535046627 @default.
• W4365457063 hasConcept C71924100 @default.
• W4365457063 hasConceptScore W4365457063C126322002 @default.
• W4365457063 hasConceptScore W4365457063C147483822 @default.
• W4365457063 hasConceptScore W4365457063C159047783 @default.
• W4365457063 hasConceptScore W4365457063C159654299 @default.

• next